PPT-Filgrastim-sndz Drugbank

ID DB09560 Indication Patients with Cancer Receiving Myelosuppressive Chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia in patients with . Figure1:Schemainterlinkingforthreedatasetsi.e.DrugBank,Sider,Diseasome. Figure2:Resourcesfromthreedierentdatasetsarefusedattheinstancelevelinordertoexploitin-formationwhicharespreadacrossdiversedatas Figure1:Schemainterlinkingforthreedatasetsi.e.DrugBank,Sider,Diseasome. Figure2:Resourcesfromthreedierentdatasetsarefusedattheinstancelevelinordertoexploitin-formationwhicharespreadacrossdiversedatas Knowledge Connect Slide Resource. This slide deck has been designed to be used as a central resource from which pertinent slides can be extracted as needed . and is not intended for use in its entirety. By. ANSHUL . SHARMA. Graduate Research Scholar. Deptt. Of Biochemical Engg & Biotechnology,. Indian Institute of Technology, Delhi . Biosimilars. Coined by EMA (European Medicine Agency). Bio-betters. Classifications. Neutropenia. A decrease in the number of circulating neutrophils (both segmented and band forms). Total Neutrophil Count (ANC) of <1,500/mm3 . ANC. = Total WBC Count x (%Segmented Neutrophils + %Band Forms). Mansoor A Khan, BS, MS, BCOP. Senior Clinical Pharmacist Oncology/Hematology/BMT. King Abdulaziz Medical City, Jeddah. Ministry of National Guard Health Affairs. SOPA Meeting on September 14, 2019. in Crown Plaza Hotel Riyadh, KSA. By: . Ranya. . Razick. , PharmD 2021. Patient Presentation. CC: liver-kidney transplant. HPI: EG is a 70-year-old F with a significant history of NASH cirrhosis. Pt presented to RUMC on 4/2 with altered mental status and abdominal distension. PT had a liver-kidney transplant on 4/7 complicated by a clotted portal vein and significant blood loss. Post-op, EG had neutropenia and hypothermia. On 4/9, she underwent an abdominal wash-out. . ID . : . DB00019 . Protein chemical . formula : . C. 845. H. 1343. N. 223. O. 243. S. 9. Protein . average . weight : . 18802.8000. Half life : . 15-80 hrs . Description. . :. . PEGylated. (at N terminus) form of human G-CSF (Granulocyte colony stimulating factor), 175 residues, produced from E. coli via bacterial fermentation. . DB00021 . Protein chemical . formula . : C. 130. H. 219. N. 43. O. 42. Protein . average . weight : . 3056.4000. Chemical name : . H-His-Ser-Asp-. Gly. -. Thr. -. Phe. -. Thr. -Ser-. Glu. -. Leu. -Ser-. Immunosuppressive Agents . RILONACEPT . . DESCRIPTION. INDICATION. Rilonacept. is a . dimeric. fusion protein consisting of portions of IL-1R and the IL-1R accessory&#13; protein linked to the . (G - CSF) fil GRA stim Patient/Caregiver Information What is Filgrastim Filgrastim is granulocyte colonstimulating factor (GCSF). It isgenerally given after chemotherapyto How does it work? Filgrasti GRANIX (tbo - filgrastim), NIVESTYM (filgrastim - aafi), RELEUKO (filgrastim - ayow), ZARXIO (filgrastim - sndz) The biosimilar medications in bold are the preferred products for claims adjudicated Hematopoietic Agents : Granulocyte Colony Stimulating Factor(GCSF)Medical olicy o. EffectiveDateJuly , 2019 Drug Medical Necessity filgrastim (Neupogen) filgrastimaafi (Nivestym)filgrastimsndz (Zarxio DB09302. Description. :. Alirocumab. is a biopharmaceutical drug approved by the FDA in July 2015 as a second line treatment for high cholesterol for adults whose LDL-cholesterol (LDL-C) is not controlled by diet and statin treatment. It is a human monoclonal antibody administered by subcutaneous injection that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.